Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

178.05
+7.614.46%
Post-market: 178.050.00000.00%19:52 EST
Volume:789.48K
Turnover:139.98M
Market Cap:8.76B
PE:-106.69
High:178.55
Open:170.51
Low:170.51
Close:170.44
52wk High:203.01
52wk Low:91.86
Shares:49.22M
Float Shares:48.62M
Volume Ratio:0.69
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6688
EPS(LYR):0.2004
ROE:-2.19%
ROA:4.35%
PB:2.57
PE(LYR):888.44

Loading ...

Charles River Laboratories International Inc. Stock Rises 4.5%, Outperforms Peers

Dow Jones
·
11 hours ago

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Nov 22

Charles River Q3 Adjusted EPS USD 2.43 Vs. IBES Estimate USD 2.34

Reuters
·
Nov 20

Charles River Exec Says Co Is Looking to Expand Its Services Portfolio in China - Jefferies Healthcare Conf

THOMSON REUTERS
·
Nov 18

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Nov 18

Argus Upgrades Charles River Laboratories International to Buy From Hold, Price Target is $200

MT Newswires Live
·
Nov 17

Charles River: SEC concluded inquiry into company, not recommeding enforcement

TIPRANKS
·
Nov 17

SEC Ends Probe Into Charles River Laboratories With No Enforcement Action

Reuters
·
Nov 17

Charles River Laboratories-Investigation Was About Inquiry Requesting to Give Information Related to Sourcing Non-Human Primates & Related Disclosures

THOMSON REUTERS
·
Nov 17

Charles River Laboratories International Inc - SEC Concludes Investigation, No Action Against Charles River Labs - SEC Filing

THOMSON REUTERS
·
Nov 17

Charles River Laboratories Presents at Jefferies Global Healthcare Conference

Reuters
·
Nov 17

Charles River Laboratories International Inc : Argus Research Raises to Buy From Hold

THOMSON REUTERS
·
Nov 17

Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Nov 14

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire
·
Nov 13

Applied Therapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 13

Did Lower Guidance and Weak Earnings Just Shift Charles River Laboratories' (CRL) Investment Narrative?

Simply Wall St.
·
Nov 13

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

GlobeNewswire
·
Nov 12

Charles River Laboratories International Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Nov 12

Charles River Labs Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Nov 12

Morgan Stanley Adjusts Charles River Laboratories International PT to $185 From $170, Maintains Equal Weight Rating

MT Newswires Live
·
Nov 11